摘要
本研究目的是对照研究美罗培南与亚胺培南西司他丁用于重症肺炎治疗的临床价值。使用随机数字表法将医院近2年收治的98例重症肺炎患者分为两组(各49例),均给予常规治疗,A组加用美罗培南,B组加用亚胺培南西司他丁。观察两组治疗前后的血气指标、炎性因子水平变化,对比两组的带呼吸机时间、临床症状改善时间和ICU入住时间等。与B组相比,A组体温恢复正常、呼吸困难改善、咳痰缓解及咳嗽停止用时均更短(P<0.05)。与治疗前相比,两组治疗后的PO_(2)、SaO_(2)及PO_(2)/FiO_(2)水平升高,PaCO_(2)水平下降(P<0.05)。A组的PO_(2)、SaO_(2)及PO_(2)/FiO_(2)更高,PaCO_(2)更低(P<0.05);与治疗前相比,两组治疗后的血清CRP、PCT、IL-6及IL-12水平下降(P<0.05),且组间对比显示A组的上述指标水平更低(P<0.05)。A组的ICU入住时间和带呼吸机时间均明显短于B组(P<0.05)。A组的总有效率显著高于B组(93.88%vs 73.47%,P<0.05),不良反应总发生率明显低于B组(6.12%vs 22.45%,P<0.05)。相比亚胺培南西司他丁,美罗培南治疗重症肺炎对血气指标及炎症反应的改善效果更为显著,病情控制效果更好,安全性更好。
To comparatively study on the clinical value of meropenem and imipenem cilastatin in the treatment of severe pneumonia,98 patients with severe pneumonia admitted in the hospital in the recent two years were divided into two groups(49 cases each)by the random number table method.Both groups were given routine treatment,with group A received meropenem and group B received cilastatin.The changes in blood gas indicators and inflammatory factor levels were observed before and after therapy,and the duration of ventilator use,clinical symptom improvement,and ICU stay were compared between the two groups.The time for body temperature to return to normal,breathing difficulties to improve,sputum relief time,and cough cessation time in group A were significantly shorter than those in group B(P<0.05).Compared with before treatment,the levels of PO_(2),SaO_(2)and PO_(2)/FiO_(2)in both groups increased after treatment,while the levels of PaCO_(2)decreased(P<0.05).The inter group comparison showed that the levels of PO_(2),SaO_(2)and PO_(2)/FiO_(2)in group A after treatment were higher than those in group B,while the levels of PaCO_(2)were lower than those in group B,with statistical significance(P<0.05).Compared with before treatment,the levels of serum CRP,PCT,IL-6,and IL-12 in both groups decreased after treatment(P<0.05),and the inter group comparison showed that the levels of the above indicators in group A were lower(P<0.05).The ICU check-in time and ventilator wearing time in group A were significantly shorter than those in group B(P<0.05).The total effective rate of group A was clearly higher than group B(93.88%vs 73.47%,P<0.05),and the total incidence of adverse reactions was clearly lower than group B(6.12%vs 22.45%,P<0.05).Compared with imipenem cilastatin,meropenem has more significant improvement effect on blood gas index and inflammatory reaction in the treatment of severe pneumonia,better disease control effect,and better drug safety.
作者
孙悦
张霞
张学洋
孙干
罗璨
SUN Yue;ZHANG Xia;ZHANG Xueyang;SUN Gan;LUO Can(Department of Pharmacy,Gaoyou People's Hospital,Yangzhou 225600,China;Gaoyou City South Economic New Zone Community Health Service Center,Yangzhou 225606,China;Department of Medicinal Materials,Huai'an Hospital,Huai'an 223200,China;Department of Infection Control of Jiangsu Provincial Hospital,Nanjing 210000,China)
出处
《药物生物技术》
2025年第6期809-812,共4页
Pharmaceutical Biotechnology
基金
江苏省高邮市人民医院院级项目(No.GYRYKY202003)。
关键词
美罗培南
亚胺培南西司他丁
重症肺炎
血气指标
炎症因子
不良反应
Meropenem
Severe pneumonia
Imipenem cilastatin
Blood gas indicators
Inflammatory factors
Adverse reactions
